Unknown

Dataset Information

0

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.


ABSTRACT:

Objective

Cellular inclusions of hyperphosphorylated tau are a hallmark of tauopathies, which are neurodegenerative disorders that include Alzheimer's disease (AD). Active and passive immunization against hyperphosphorylated tau has been shown to attenuate phenotypes in model mice. We developed new monoclonal antibodies to hyperphosphorylated tau and sought high therapeutic efficacy for future clinical use.

Methods

Using more than 20 antibodies, we investigated which sites on tau are phosphorylated early and highly in the tauopathy mouse models tau609 and tau784. These mice display tau hyperphosphorylation, synapse loss, memory impairment at 6 months, and tangle formation and neuronal loss at 15 months. We generated mouse monoclonal antibodies to selected epitopes and examined their effects on memory and tau pathology in aged tau609 and tau784 mice by the Morris water maze and by histological and biochemical analyses.

Results

Immunohistochemical screening revealed that pSer413 is expressed early and highly. Monoclonal antibodies to pSer413 and to pSer396 (control) were generated. These antibodies specifically recognized pathological tau in AD brains but not normal tau in control brains according to Western blots. Representative anti-pSer413 and anti-pSer396 antibodies were injected intraperitoneally into 10-11- or 14-month-old mice once a week at 0.1 or 1 mg/shot 5 times. The anti-pSer413 antibody significantly improved memory, whereas the anti-pSer396 antibodies showed less effect. The cognitive improvement paralleled a reduction in the levels of tau hyperphosphorylation, tau oligomer accumulation, synapse loss, tangle formation, and neuronal loss.

Interpretation

These results indicate that pSer413 is a promising target in the treatment of tauopathy.

SUBMITTER: Umeda T 

PROVIDER: S-EPMC4369274 | biostudies-literature | 2015 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice.

Umeda Tomohiro T   Eguchi Hiroshi H   Kunori Yuichi Y   Matsumoto Yoichi Y   Taniguchi Taizo T   Mori Hiroshi H   Tomiyama Takami T  

Annals of clinical and translational neurology 20150109 3


<h4>Objective</h4>Cellular inclusions of hyperphosphorylated tau are a hallmark of tauopathies, which are neurodegenerative disorders that include Alzheimer's disease (AD). Active and passive immunization against hyperphosphorylated tau has been shown to attenuate phenotypes in model mice. We developed new monoclonal antibodies to hyperphosphorylated tau and sought high therapeutic efficacy for future clinical use.<h4>Methods</h4>Using more than 20 antibodies, we investigated which sites on tau  ...[more]

Similar Datasets

| S-EPMC6805661 | biostudies-literature
| S-EPMC4416899 | biostudies-literature
| S-EPMC7365083 | biostudies-literature
| S-EPMC10411817 | biostudies-literature
| S-EPMC5792300 | biostudies-literature
| S-EPMC9466354 | biostudies-literature
| S-EPMC6937375 | biostudies-literature
| S-EPMC7001291 | biostudies-literature
| S-EPMC4205609 | biostudies-literature
| S-EPMC4303592 | biostudies-literature